Greenleaf Trust Increases Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Greenleaf Trust raised its holdings in DexCom, Inc. (NASDAQ:DXCM) by 19.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 14,095 shares of the medical device company’s stock after buying an additional 2,255 shares during the quarter. Greenleaf Trust’s holdings in DexCom were worth $1,096,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the business. Versant Capital Management Inc purchased a new position in shares of DexCom in the 4th quarter valued at approximately $25,000. Riverview Trust Co increased its stake in DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after purchasing an additional 232 shares in the last quarter. Heck Capital Advisors LLC purchased a new position in shares of DexCom in the fourth quarter worth $38,000. RPg Family Wealth Advisory LLC acquired a new stake in shares of DexCom during the third quarter worth $57,000. Finally, Covestor Ltd grew its holdings in shares of DexCom by 53.7% during the third quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock valued at $64,000 after buying an additional 335 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Activity

In other DexCom news, COO Jacob Steven Leach sold 2,634 shares of the business’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the sale, the chief operating officer now directly owns 268,644 shares in the company, valued at approximately $23,347,850.04. The trade was a 0.97 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Kevin R. Sayer sold 33,359 shares of the firm’s stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the transaction, the chief executive officer now owns 319,037 shares in the company, valued at approximately $27,727,505.67. This trade represents a 9.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 42,342 shares of company stock worth $3,628,069 over the last three months. 0.30% of the stock is currently owned by corporate insiders.

DexCom Price Performance

Shares of DexCom stock opened at $87.05 on Tuesday. The firm has a market cap of $34.00 billion, a PE ratio of 52.13, a P/E/G ratio of 2.23 and a beta of 1.14. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The business has a 50-day moving average price of $80.77 and a 200 day moving average price of $75.94.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Oppenheimer reduced their target price on DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Canaccord Genuity Group lifted their target price on DexCom from $89.00 to $99.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Redburn Atlantic upgraded DexCom from a “neutral” rating to a “buy” rating and upped their target price for the company from $85.00 to $115.00 in a research report on Monday. StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Finally, Baird R W raised shares of DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Four investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $98.41.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.